Biphasic insulin aspart in type 2 diabetes mellitus: An evidence-based medicine review

Clinical Drug Investigation

Volumn 27, Issue 5, 2007, Pages 299-324

  Gough, S C L ^a   Tibaldi, J ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Queens Endocrine and Diabetes Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIPHASIC INSULIN; BIPHASIC INSULIN ASPART 30; C PEPTIDE; FRUCTOSAMINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; LABORATORY TEST; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SATISFACTION; WEIGHT GAIN; WELLBEING;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 34249111237     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727050-00002     Document Type: Review

References (57)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 (5): 1047-53
2. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23: 381-9
3. American Diabetes Association. Standards of Medical care Diabetes Care in diabetes. 2005; 28 Suppl. 1: 4-36
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53
6. Ceriello A. Post-prandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7
7. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28 (2): 260-5
8. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26 (3): 881-5
9. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998; 158 (2): 134-40
10. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28 (2): 103-17
11. Lean ME, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. BMJ (Clinical research ed.) 1985; 290 (6462): 105-8
12. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001; 40: 641-59
13. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56 (5): 399-403
14. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20 (10): 1612-4
15. Lai T, Leung GM, Wong VWY, et al. How evidence-based are publications in clinical ophthalmic journals? Invest Ophthalmol Vis Science 2006; 47: 1831-8
16. Dias M. Neurosurgical causes of scoliosis in patients with myelomeningocele: an evidence-based literature review. J Neurosurgery 2005; 103 (1, Suppl. S): 24-35
17. Haycox A. Insulin aspart: an evidence-based medicine review. Clin Drug Invest 2004; 24 (12): 695-717
18. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psych 2005; 162 (11): 1996-2021
19. Oxford Centre for Evidence-based Medicine 2005. Frequently asked questions [online]. Available from URL: http://www.cebm.net/levels_faq.asp [Accessed 2005 Dec 15]
20. American Diabetes Association. Standards of Medical care for patients with diabetes mellitus. Diabetes Care 2002; 25 Suppl. 1: S33-49
21. Moses A, Raskin P, Hu P, et al. Serum 1,5-anhydroglucitol as a marker of glycemic control in subjects receiving twice-daily biphasic insulin aspart 70/30 (BiAsp 70/30) vs. once-daily Insulin glargine in patients with type 2 diabetes mellitus on oral antidiabetic agents [abstract no. 951194]. American Diabetes Association: 65th Annual Scientific Sessions, San Diego (CA) June 10-14, 2005
22. Luzio S, Dunseath G, Peter R, et al. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49 (6): 1163-8
23. Christiansen JS, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves post-prandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5 (6): 446-54
24. Brod M, Cobden D, Lammert M, et al. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007; 5: 8
25. Ligthelm R. Number of daily insulin injections required does not affect patient well being [abstract no. 951123]. American Diabetes Association: 65th Annual Scientific Sessions, San Diego (CA) June 10-14, 2005
26. Kann P, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006; 114: 527-32
27. Garber A, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice- or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006; 8 (1): 58-66
28. Kvapil M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 2006; 8 (1): 39-48
29. Wan Mohamad W. Adding NovoLog Mix 70/30 once or twice daily is more efficacious than optimizing oral treatment in patients with type 2 diabetes. Diabetes 2005; 54 Suppl. 1: A510
30. Ushakova O, Sokolovskaya V, Morozova A, et al. Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premix analogue, is an effective and well tolerated starter insulin in type 2 diabetes [abstract no. 951909]. American Diabetes Association: 65th Annual Scientific Sessions, San Diego (CA) June 10-14, 2005
31. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004; 26 (4): 531-40
32. Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17 (6): 307-13
33. Lund SS, Tarnow L, Pedersen OB, et al. Effect of BIAsp 30 (NovoLog Mix 70/30) in combination with oral hypogly-chiacaemic agents (OHA) on glycaemic control in non-obese patients with type 2 diabetes [abstract no. 951226]. American Diabetes Association: 65th Annual Scientific Sessions, San Diego (CA) June 10-14, 2005
34. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract 2006; 72 (3): 265-70
35. Raz I, Stranks S, Filipczak R, et al. In inadequately controlled patients with type 2 diabetes, biphasic insulin aspart 30 combined with pioglitazone provides better glycaemic control than biphasic insulin aspart 30 monotherapy or pioglitazone/sulphonylurea combination. Diabetologia 2003; 46 Suppl. 2: A8
36. Raz I, Stranks S, Filipczak R, et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomizes, open-label study. Clin Ther 2005; 27 (9): 1432-43
37. Raz I, Mouritzen U, Vaz J, et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003; 25 (12): 3109-23
38. Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003; 46 Suppl. 2: A 270
39. Boehm BO, Vaz JA, Brondsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15 (8): 496-502
40. Yamada S, Tamada T, Suzuki R. Premixed 70/30 insulin aspart suspension improves insulin therapy related QOL in comparison with premixed 70/30 Human insulin. Diabetes 2005; 54 Suppl. 1: A119
41. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24 (4): 530-9
42. Hermansen K, Colombo M, Storgaard H, et al. Improved post-prandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25 (5): 883-8
43. Kapitza C, Rave K, Ostrowski K, et al. Reduced post-prandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabet Med 2004; 21 (5): 500-1
44. McNally P, Dean J, Morris A, et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. In press
45. Lammert M, Palmer A, Roze S, et al. Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish and UK settings. Value Health 2004; 7 (6): 649
46. Schmoelzer I, de Campo A, Pressl H, et al. Biphasic insulin aspart compared to biphasic human Insulin reduces post-prandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2005; 113: 176-81
47. Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab 2007; 9 (1), 103-113
48. Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005; 21 (12): 2063-71
49. Minshall ME, Roze S, Palmer AJ, et al. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clin Ther 2005; 27 (6): 940-50
50. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327 (20): 1426-33
51. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130 (5): 389-96
52. Huang A, Raskin P. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 2005; 4: 205-20
53. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24 (7): 1226-32
54. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56 (4): 251-7
55. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-89
56. De Grauw WJ, van de Lisdonk EH, van Gerwen WH, et al. Insulin therapy in poorly controlled type 2 diabetic patients: does it affect quality of life? Br J Gen Pract 2001; 51 (468): 527-32
57. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62 (13): 1945-81